EP0242653B1 - Tpa-containing medical composition and use thereof - Google Patents

Tpa-containing medical composition and use thereof Download PDF

Info

Publication number
EP0242653B1
EP0242653B1 EP87104825A EP87104825A EP0242653B1 EP 0242653 B1 EP0242653 B1 EP 0242653B1 EP 87104825 A EP87104825 A EP 87104825A EP 87104825 A EP87104825 A EP 87104825A EP 0242653 B1 EP0242653 B1 EP 0242653B1
Authority
EP
European Patent Office
Prior art keywords
tpa
meglumine
salt
medical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP87104825A
Other languages
German (de)
French (fr)
Other versions
EP0242653A1 (en
Inventor
Fumio Kakimoto
Naoki Asakawa
Yasuo Ishibashi
Yasuo Miyake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to AT87104825T priority Critical patent/ATE56147T1/en
Publication of EP0242653A1 publication Critical patent/EP0242653A1/en
Application granted granted Critical
Publication of EP0242653B1 publication Critical patent/EP0242653B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • This invention relates to a medical composition containing a tissue Plasminogen Activator (hereinafter called "tPA"). More specifically, the present invention relates to a tPA-containing medical composition with increased water-solubility of tPA, which comprises tPA in combination with meglumine or a salt thereof.
  • tPA tissue Plasminogen Activator
  • tPA acts on plasminogen in a living body to form plasmin and this plasmin destroys fibrin networks of thrombi to dissolve the same and tPA is hence a substance useful for the treatment of circulatory disorders caused by the formation of thrombi.
  • tPA is a protein having an extremely low solubility in water. It is therefore very difficult to formulate tPA into a preparation which is administered after its dissolution in water, for example, into an injection. This is the greatest obstacle for the utilization of tPA in actual therapy.
  • An object of this invention is therefore to provide a tPA-containing medical composition in which the water-solubility of tPA has been increased to a degree sufficient to permit the use of tPA in therapy.
  • the present inventors carried out a variety of investigations with a view toward developing a technique to increase the solubility of tPA in water. As a result, it was found that a composition with improved water-solubility of tPA can be obtained by incorporating a diisocyanate-bound partial hydrolyzate of gelatin or arginine.
  • Application for patents have already been filed on the basis of these findings (Japanese Patent Application Nos. 198,62g/1985 and 258,624/1985).
  • tPA tissue Plasminogen Activator
  • tPA may be one extracted from a natural source or one obtained from a microorganism prepared artificially by a bioengineering technique or a culture broth of animal cells. This invention is not limited to any specific origin for tPA.
  • Meglumine i.eN-methyl-glucamine
  • a salt thereof is employed in this invention.
  • meglumine available in a salt form may be used directly as the salt of meglumine
  • the salt of meglumine can be provided by incorporating both meglumine and an inorganic or organic acid in a composition of this invention.
  • Illustrative examples of such a salt may include the hydrochloride, acetate, lactate, and gluconate.
  • the medical composition of the present invention includes not only a solid or aqueous composition in which tPA and meglumine or a salt thereof are contained in combination but also a composition in such a form that tPA and meglumine or a salt thereof are individually packed, such as a vial containing lyophilized tPA and an ampule containing an aqueous solution of meglumine or a salt thereof and adapted for the dissolution of the lyophilized tPA, like an injection which can be formulated prior to its use.
  • composition of the present invention may further contain auxiliary ingredients routinely employed in the formulation of dosable medical preparations, for example, one or more fillers, stabilizers, buffers and isotonic agents as needed.
  • auxiliary ingredients routinely employed in the formulation of dosable medical preparations, for example, one or more fillers, stabilizers, buffers and isotonic agents as needed.
  • composition of this invention may be carried out by a usual production method for a desired preparation form.
  • a preparation method will next be described by way of example.
  • An aqueous tPA solution is filled in portions in vials and is then lyophilized, thereby providing vials enclosing tPA-containing powder.
  • an aqueous solution of the additive according to this invention is filled in portions in vials.
  • One of the former vials is combined with one of the latter vials to provide a composition of this invention.
  • solubility of tPA in water has been increased, whereby a high- concentration aqueous solution of tPA has been provided.
  • a tPA-containing injection having a high potency can be provided.
  • the solubility of tPA in water was 2100 U/mi (U is a potency unit) when meglumine was not added while the addition of meglumine increased it to 17,000 U/mi at 1%, 85,000 UlMi at 2% and 331,000 UlMi at 5% respectively, in which U/ml defines the solubility of tPA in water.
  • U/mi U is a potency unit
  • aqueous solution containing 10 g of meglumine and 3 g of mannitol was adjusted to pH 7 with hydrochloric acid. The total volume of the thus-adjusted solution was 100 mi. Ten million units of tPA were then added, whereby an aqueous solution containing 1,000,000 units of tPA was prepared under sterile conditions. One-ml portions of the aqueous solution were pipetted in vials, lyophilized and then sealed hermetically.
  • ampules each containing 2 ml of distilled water for injection were prepared for dissolution.
  • tPA powder Ten million units of tPA powder, which had been prepared under sterile conditions, and 3 g of sterile mannitol were mixed uniformly. In vials, the resultant mixture was filled and hermetically sealed in portions so that tPA was contained in an amount of 100,000 units per vial.
  • an aqueous solution containing 10 g of meglumine was adjusted to pH 7 with lactic acid under sterile conditions.
  • the total volume of the thus-adjusted aqueous solution was 200 mP.
  • Ampules each containing 2 ml of the resultant aqueous solution were prepared for dissolution.
  • tPA samples in an amount equivalent to 400,000 units were weighed separately in small testing tubes, to which there were respectively added 1 mP of aqueous solutions containing meglumine and adjusted to pH 7 respectively with various acids in an amount equivalent to the meglumine. After stirring, the resultant mixtures were separately centrifuged to obtain super natants as samples. Incidentally, the concentration of meglumine in each sample was 2%.
  • aqueous solutions were prepared in exactly the same manner as the test samples except that in place of meglumine, sodium hydroxide was used in an amount equal in mole to the meglumine, thereby providing comparative samples.
  • a predetermined amount of each sample was taken out and diluted with 0.1 M tris-HC£ buffer (pH 8; BSA was contained), followed by measurement of tPA activity (U/ml) by a fibrin plate.
  • Results are summarized in Table 1. Numerical values given in Table 1 indicate tPA activities (U/ml). From Table 1, it is envisaged that the solubility of tPA is increased by an addition of a suitably-selected acid and is increased further to a significant extent by an addition of meglumine.
  • Test samples were provided in the same manner as in Example 1 except that the concentration of meglumine was 1%, 2% and 5% and hydrochloric acid was employed singly as an acid, followed by measurement of their tPA activities (U/ml). Results are shown in Table 2. It is understood that the solubility of tPA increases as the concentration of meglumine increases.

Abstract

A medical composition contains a tissue Plasminogen Activator (tPA) in combination with meglumine or a salt thereof. The use of the composition in the preparation of a medicament for the treatment of circulatory disorders is also disclosed.

Description

  • This invention relates to a medical composition containing a tissue Plasminogen Activator (hereinafter called "tPA"). More specifically, the present invention relates to a tPA-containing medical composition with increased water-solubility of tPA, which comprises tPA in combination with meglumine or a salt thereof.
  • It is known that tPA acts on plasminogen in a living body to form plasmin and this plasmin destroys fibrin networks of thrombi to dissolve the same and tPA is hence a substance useful for the treatment of circulatory disorders caused by the formation of thrombi.
  • However, tPA is a protein having an extremely low solubility in water. It is therefore very difficult to formulate tPA into a preparation which is administered after its dissolution in water, for example, into an injection. This is the greatest obstacle for the utilization of tPA in actual therapy.
  • An object of this invention is therefore to provide a tPA-containing medical composition in which the water-solubility of tPA has been increased to a degree sufficient to permit the use of tPA in therapy.
  • The present inventors carried out a variety of investigations with a view toward developing a technique to increase the solubility of tPA in water. As a result, it was found that a composition with improved water-solubility of tPA can be obtained by incorporating a diisocyanate-bound partial hydrolyzate of gelatin or arginine. Application for patents have already been filed on the basis of these findings (Japanese Patent Application Nos. 198,62g/1985 and 258,624/1985).
  • The present inventors have proceeded with a further investigation. As a result, it has now been found that an addition of meglumine or a salt thereof to tPA can significantly increase the solubility of tPA further in water, leading to completion of this invention.
  • In one aspect of this invention, there is thus provided a medical composition containing a tissue Plasminogen Activator (tPA), which comprises tPA in combination with meglumine or a salt thereof.
  • The solubility of tPA has been increased to a considerable extent by the addition of meglumine or the salt thereof.
  • The above and other objects, features and advantages of the present invention will become apparent from the following description and the appended claims.
  • In the present invention, tPA may be one extracted from a natural source or one obtained from a microorganism prepared artificially by a bioengineering technique or a culture broth of animal cells. This invention is not limited to any specific origin for tPA.
  • Meglumine (i.eN-methyl-glucamine) or a salt thereof is employed in this invention. Although meglumine available in a salt form may be used directly as the salt of meglumine, the salt of meglumine can be provided by incorporating both meglumine and an inorganic or organic acid in a composition of this invention. Illustrative examples of such a salt may include the hydrochloride, acetate, lactate, and gluconate.
  • The medical composition of the present invention includes not only a solid or aqueous composition in which tPA and meglumine or a salt thereof are contained in combination but also a composition in such a form that tPA and meglumine or a salt thereof are individually packed, such as a vial containing lyophilized tPA and an ampule containing an aqueous solution of meglumine or a salt thereof and adapted for the dissolution of the lyophilized tPA, like an injection which can be formulated prior to its use.
  • The composition of the present invention may further contain auxiliary ingredients routinely employed in the formulation of dosable medical preparations, for example, one or more fillers, stabilizers, buffers and isotonic agents as needed.
  • The production of the composition of this invention may be carried out by a usual production method for a desired preparation form. A preparation method will next be described by way of example. An aqueous tPA solution is filled in portions in vials and is then lyophilized, thereby providing vials enclosing tPA-containing powder. On the side, an aqueous solution of the additive according to this invention is filled in portions in vials. One of the former vials is combined with one of the latter vials to provide a composition of this invention.
  • It is an effect of this invention that the solubility of tPA in water has been increased, whereby a high- concentration aqueous solution of tPA has been provided. As a specific example, a tPA-containing injection having a high potency can be provided. According to experiments which will be described subsequently, the solubility of tPA in water was 2100 U/mi (U is a potency unit) when meglumine was not added while the addition of meglumine increased it to 17,000 U/mi at 1%, 85,000 UlMi at 2% and 331,000 UlMi at 5% respectively, in which U/ml defines the solubility of tPA in water. Namely, the significant effects of meglumine for the increase of the solubility of tPA in water are observed.
    • Examples
  • The present invention will be described more specifically by the following Examples.
    • Example 1
  • An aqueous solution containing 10 g of meglumine and 3 g of mannitol was adjusted to pH 7 with hydrochloric acid. The total volume of the thus-adjusted solution was 100 mi. Ten million units of tPA were then added, whereby an aqueous solution containing 1,000,000 units of tPA was prepared under sterile conditions. One-ml portions of the aqueous solution were pipetted in vials, lyophilized and then sealed hermetically.
  • Separately, ampules each containing 2 ml of distilled water for injection were prepared for dissolution.
    • Example 2
  • Ten million units of tPA powder, which had been prepared under sterile conditions, and 3 g of sterile mannitol were mixed uniformly. In vials, the resultant mixture was filled and hermetically sealed in portions so that tPA was contained in an amount of 100,000 units per vial.
  • Separately, an aqueous solution containing 10 g of meglumine was adjusted to pH 7 with lactic acid under sterile conditions. The total volume of the thus-adjusted aqueous solution was 200 mP. Ampules each containing 2 ml of the resultant aqueous solution were prepared for dissolution.
  • Advantages of this invention will next be described by the following Experiments.
    • Experiment 1:
  • tPA samples in an amount equivalent to 400,000 units were weighed separately in small testing tubes, to which there were respectively added 1 mP of aqueous solutions containing meglumine and adjusted to pH 7 respectively with various acids in an amount equivalent to the meglumine. After stirring, the resultant mixtures were separately centrifuged to obtain super natants as samples. Incidentally, the concentration of meglumine in each sample was 2%. In addition, aqueous solutions were prepared in exactly the same manner as the test samples except that in place of meglumine, sodium hydroxide was used in an amount equal in mole to the meglumine, thereby providing comparative samples.
  • A predetermined amount of each sample was taken out and diluted with 0.1 M tris-HC£ buffer (pH 8; BSA was contained), followed by measurement of tPA activity (U/mℓ) by a fibrin plate.
  • Results are summarized in Table 1. Numerical values given in Table 1 indicate tPA activities (U/mℓ). From Table 1, it is envisaged that the solubility of tPA is increased by an addition of a suitably-selected acid and is increased further to a significant extent by an addition of meglumine.
    Figure imgb0001
    • Experiment 2:
  • Test samples were provided in the same manner as in Example 1 except that the concentration of meglumine was 1%, 2% and 5% and hydrochloric acid was employed singly as an acid, followed by measurement of their tPA activities (U/mℓ). Results are shown in Table 2. It is understood that the solubility of tPA increases as the concentration of meglumine increases.
    Figure imgb0002

Claims (7)

1. A medical composition consisting of a tissue Plasminogen Activator (tPA), and meglumine or a salt thereof.
2. The medical composition as claimed in Claim 1, wherein meglumine is contained in form of a salt selected from meglumine hydrochloride, acetate, lactate and gluconate.
3. The medical composition as claimed in Claim 2, wherein the salt has been formed by incorporating meglumine and the corresponding inorganic or organic acid in the composition.
4. The medical composition as claimed in Claim 1, wherein tPA and meglumine or the salt thereof are contained in separate packages of the same set.
5. The medical composition as claimed in Claim 4, wherein the meglumine or the salt thereof is in the form of an aqueous solution thereof.
6. The medical composition as claimed in Claim 1, further comprising mannitol.
7. Use of the composition according to any of claims 1 to 6 in the preparation of a medicament for the treatment of circulatory disorders.
EP87104825A 1986-04-02 1987-04-01 Tpa-containing medical composition and use thereof Expired - Lifetime EP0242653B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87104825T ATE56147T1 (en) 1986-04-02 1987-04-01 MEDICINAL PREPARATION CONTAINING T-PA AND USE THEREOF.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61074370A JPH0678241B2 (en) 1986-04-02 1986-04-02 tPA pharmaceutical composition
JP74370/86 1986-04-02

Publications (2)

Publication Number Publication Date
EP0242653A1 EP0242653A1 (en) 1987-10-28
EP0242653B1 true EP0242653B1 (en) 1990-09-05

Family

ID=13545204

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87104825A Expired - Lifetime EP0242653B1 (en) 1986-04-02 1987-04-01 Tpa-containing medical composition and use thereof

Country Status (8)

Country Link
US (1) US4985245A (en)
EP (1) EP0242653B1 (en)
JP (1) JPH0678241B2 (en)
AT (1) ATE56147T1 (en)
CA (1) CA1289472C (en)
DE (1) DE3764697D1 (en)
ES (1) ES2031846T3 (en)
GR (1) GR3000751T3 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2520975B2 (en) * 1989-09-21 1996-07-31 三井東圧化学株式会社 Thrombolytic agent containing tissue plasminogen activator or its derivative
DE3942142A1 (en) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh STABILIZATION OF GLYCOSYLATED T-PA
DE3942143A1 (en) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-PA PRO STABILIZATION
DE3942141A1 (en) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2P PRO STABILIZATION
GB0007239D0 (en) * 2000-03-24 2000-05-17 Nycomed Imaging As Use
JP5468221B2 (en) * 2008-08-04 2014-04-09 株式会社 メドレックス Intravenous dispersion formulation of poorly soluble drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5137343B2 (en) * 1972-12-07 1976-10-15
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3584902D1 (en) * 1984-02-29 1992-01-30 Asahi Chemical Ind AQUEOUS SOLUTION OF AN INCREASED CONCENTRATION OF TISSUE PLASMINOGEN ACTIVATOR AND PRODUCTION METHOD.

Also Published As

Publication number Publication date
ATE56147T1 (en) 1990-09-15
EP0242653A1 (en) 1987-10-28
JPS62234030A (en) 1987-10-14
JPH0678241B2 (en) 1994-10-05
ES2031846T3 (en) 1996-07-16
US4985245A (en) 1991-01-15
DE3764697D1 (en) 1990-10-11
CA1289472C (en) 1991-09-24
GR3000751T3 (en) 1991-10-10

Similar Documents

Publication Publication Date Title
EP0123304B1 (en) A method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same
US4965203A (en) Purified thrombin preparations
EP0228862B1 (en) Stabilized human tissue plasminogen activator compositions
EP0444692B1 (en) Thrombin composition for oral administration
US3868358A (en) Protamine-insulin product
EP0217379B1 (en) Thrombolytic composition and a process for production thereof
Hagan et al. Purification and biochemical properties of human plasminogen
HU198264B (en) Process for producing antithrombotic pharmaceutical compositions
Lewis et al. Studies on a Proteolytic Enzyme System of the Blood: V. Activation of Profibrinolysin by Trypsin
EP0218112B1 (en) Composition containing tissue plasminogen activator
US5034225A (en) Stabilized human tissue plasminogen activator compositions
EP0242653B1 (en) Tpa-containing medical composition and use thereof
EP0277096B1 (en) Improved thrombin preparations
JPS638339A (en) Medicinal composition for non-oral administration
JP2708749B2 (en) Injectable composition containing modified tPA
US5366730A (en) Stabilized compositions having human tissue type plasminogen activator enzymatic activity
CA2046598C (en) T-pa solubilisation
JPH0424331B2 (en)
Ferguson Stability of Prothrombin in the Presence of Thrombin
JPS62120321A (en) Tpa-containing pharmaceutical composition
JPS62123130A (en) Tpa-containing drug composition having increased water solubility
Randall et al. Stable, Reduced, Desiccated Streptolysin “O.”
US2902406A (en) Method for preparing iodinated thyroid
Jaques A Biological Method of Assay of hyaluronidase
SU1706627A1 (en) Remedy sterilization and castration of mammalian males of the different ages - "kanaphen b"

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19880330

17Q First examination report despatched

Effective date: 19890928

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 56147

Country of ref document: AT

Date of ref document: 19900915

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3764697

Country of ref document: DE

Date of ref document: 19901011

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3000751

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2031846

Country of ref document: ES

Kind code of ref document: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19930406

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 19940402

ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 87104825.2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19960325

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19960410

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19960411

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19960417

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19960418

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19960424

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19960429

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19960430

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19960501

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19960612

Year of fee payment: 10

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2031846

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970401

Ref country code: GB

Effective date: 19970401

Ref country code: AT

Effective date: 19970401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19970402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970430

Ref country code: BE

Effective date: 19970430

BERE Be: lapsed

Owner name: EISAI CO. LTD

Effective date: 19970430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19971031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19971101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19970401

REG Reference to a national code

Ref country code: GR

Ref legal event code: MM2A

Free format text: 3000751

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980101

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19971101

EUG Se: european patent has lapsed

Ref document number: 87104825.2

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20001102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050401